Literature DB >> 27592303

Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?

Claudio Zavaglia1, Stefano Okolicsanyi2, Lucia Cesarini3, Chiara Mazzarelli3, Valerio Pontecorvi2, Antonio Ciaccio2, Mario Strazzabosco2, Luca Saverio Belli4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27592303     DOI： 10.1016/j.jhep.2016.08.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  23 in total

1.  Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Authors:  N Saraiya; A C Yopp; N E Rich; M Odewole; N D Parikh; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2018-05-30       Impact factor: 8.171

Review 2.  Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.

Authors:  Kimberly E Daniel; Adnan Said
Journal:  Curr Gastroenterol Rep       Date:  2018-04-05

Review 3.  Hepatocellular Cancer: Is Recurrence Inevitable?

Authors:  Levent Doganay
Journal:  J Gastrointest Cancer       Date:  2017-09

4.  Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

Authors:  Xavier Adhoute; Paul Castellani; Marc Bourlière
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-18

5.  Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.

Authors:  Marcus-Alexander Wörns; Peter Robert Galle; Stefan Zeuzem; Peter Schirmacher; Michael Manns; Arndt Vogel
Journal:  Dtsch Arztebl Int       Date:  2017-09-04       Impact factor: 5.594

Review 6.  Interaction Between Hepatocellular Carcinoma and Hepatitis C Eradication With Direct-acting Antiviral Therapy.

Authors:  Venkata Rajesh Konjeti; Binu V John
Journal:  Curr Treat Options Gastroenterol       Date:  2018-06

Review 7.  AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.

Authors:  Amit G Singal; Joseph K Lim; Fasiha Kanwal
Journal:  Gastroenterology       Date:  2019-03-13       Impact factor: 22.682

8.  Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.

Authors:  Carmen M Preda; Cristian Baicus; Irina Sandra; Alexandru Oproiu; Teodora Manuc; Ileana Constantinescu; Daniel Gavrila; Mircea Diculescu; Radu Dumitru; Catalin Vasilescu; Cristian Tieranu; Doina Istratescu; Theodor Voiosu; Mircea Manuc
Journal:  United European Gastroenterol J       Date:  2019-03-29       Impact factor: 4.623

9.  Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.

Authors:  Yoshihiko Ooka; Kanda Miho; Obi Shuntaro; Masato Nakamura; Sadahisa Ogasawara; Eiichiro Suzuki; Shin Yasui; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Osamu Yokosuka; Naoya Kato; Hitoshi Mochizuki; Masao Omata
Journal:  Hepatol Int       Date:  2018-09-21       Impact factor: 6.047

10.  Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.

Authors:  Annsa C Huang; Neil Mehta; Jennifer L Dodge; Francis Y Yao; Norah A Terrault
Journal:  Hepatology       Date:  2018-05-16       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.